Impact of an interchange program to support use of insulin pens

American Journal of Health-System Pharmacy

Volumn 68, Issue 14, 2011, Pages 1349-1352

  Ward, Leah G ^a   Aton, Sara S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Costs; Drug administration; Economics; Errors, medication; Hospitals; Insulin; Insulin aspart; Insulin detemir; Insulins; Needles

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; PIG INSULIN; RECOMBINANT HUMAN INSULIN;

ARTICLE; CLINICAL PROTOCOL; COST CONTROL; DRUG COST; DRUG DELIVERY SYSTEM; HEALTH PROGRAM; HUMAN; INCIDENT REPORT; INTERCHANGE PROGRAM; MAJOR CLINICAL STUDY; MEDICAL ERROR; NEEDLESTICK INJURY; PATIENT SAFETY; PRIORITY JOURNAL; SYRINGE;

EID: 79960632917     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100535     Document Type: Article

References (14)

1. Institute for Safe Medication Practices. Considering insulin pens for routine hospital use? Consider this . . .. www.ismp.org/Newsletters/acutecare/ articles/20080508.asp (accessed 2011 Feb 25).
2. Davis EM, Christensen CM, Nystrom KK et al. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health-Syst Pharm. 2008; 65:1347-57.
3. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila). 2004; 43:69-74. (Pubitemid 38112268)
4. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care. 1999; 22:137-40. (Pubitemid 29028310)
5. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using peninjectors and syringes. Arch Dis Child. 1998; 79:59-62. (Pubitemid 28331256)
6. Korytkowski M, Bell D, Jacobsen C et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003; 25:2836-48. (Pubitemid 37510593)
7. Luzio S, Peter R, Dunseath GJ et al. A comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h period. Diabetes Res Clin Pract. 2008; 79:269-75.
8. Heise T, Nosek L, Spitzer H et al. Insulin glulisine: a faster onset of action compared to insulin lispro. Diabetes, Obesity Metabolism. 2007; 9:746-53. (Pubitemid 47261856)
9. Homko C, Deluzio A, Jimenez C et al. Comparison of insulin aspart and lispro. Diabetes Care. 2003; 26:2027-31.
10. Porcellati F, Luzio S, Rossetti P et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007; 30:2447-52. (Pubitemid 47547770)
11. Hollander P, Cooper J, Bregnhog J et al. A 52-week, multinational, open-label, parallel group, non-inferiority, treat-totarget trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008; 30:1976-87.
12. Klein O, Lynge J, Endahl L et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes, Obesity, Metabolism. 2007; 9:290-9. (Pubitemid 46502046)
13. King A. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glyaecemic control over 24h in patients with type 2 diabetes: a double-blind, randomized, cross-over study. Diabetes, Obesity, Metabolism. 2009; 11:69-71.
14. Early communication about safety of Lantus (insulin glargine). www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm169722.htm (accessed 2011 Feb 25).